Study on preventing pneumocystis pneumonia in autoimmune disease
Treatments studied
Part of Immune system & allergy, Infections, Lungs & breathing, Skin clinical trials.
This trial tests whether a preventive treatment can stop pneumocystis pneumonia (a lung infection) in people with autoimmune inflammatory rheumatic diseases who are taking steroids or other immune-suppressing medicines. It aims to find the safest and most effective way to protect you from this serious infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an autoimmune inflammatory rheumatic disease (like lupus, rheumatoid arthritis, or similar).
- You are currently taking steroids or other medicines that suppress your immune system.
- You are 18 years old or older.
- You have not yet received the standard preventive treatment (TMP/SMZ) for pneumocystis pneumonia.
- You do not have severe liver, kidney, or blood problems, and you do not have HIV, cancer, or an organ transplant.
- You are not pregnant, breastfeeding, or allergic to sulfa drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This trial tests how long kidney transplant patients should take a common antibiotic (sulfamethoxazole) to prevent a lung infection called PJP. You may join if you are between 18 and 70 and have had a kidney transplant.
This trial tests whether giving steroids (anti-inflammatory medicines) to people with a severe lung infection called Pneumocystis pneumonia (PJP) can improve outcomes. It is for patients who are in the ICU and do not have HIV, which is a different group than typical PJP patients.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
This study tests whether stopping methotrexate for a short time before getting the pneumonia vaccine (PCV20) helps your body build a stronger immune response. It is for people with autoimmune rheumatic diseases like rheumatoid arthritis or lupus whose disease is under control.
This trial tests whether giving a special antibiotic treatment to clear a common lung fungus (Pneumocystis jirovecii) can reduce how often COPD flare-ups happen. If you qualify, this might help you have fewer severe episodes.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.